/
ACIU
$2.57-$0.05 (-1.91%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$266.6M
102M shares
52-week range
$2.03 – $4.00
27% from low
Exchange
NASDAQ
CS
Change$-3.92
AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
www.acimmune.com- Employees
- 122
- IPO / List date
- Sep 23, 2016
Held by traders on TradeandTell
No one on the platform currently holds ACIU.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 624,367 | $1.7M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ACIU yet.
